OXLUMO (lumasiran)
Primary Hyperoxaluria Type 1 (PH1)
ApprovedCommercial
Key Facts
Indication
Primary Hyperoxaluria Type 1 (PH1)
Phase
Approved
Status
Commercial
Company
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.
View full company profile